Barclays’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.88M | Sell |
116,657
-330,063
| -74% | -$9.84M | ﹤0.01% | 1976 |
|
|
2025
Q4 | $13.3M | Sell |
446,720
-11,505
| -3% | -$376K | ﹤0.01% | 1486 |
|
|
2025
Q3 | $16.6M | Sell |
458,225
-162,321
| -26% | -$5.35M | ﹤0.01% | 1343 |
|
|
2025
Q2 | $22.3M | Buy |
620,546
+367,452
| +145% | +$13.7M | 0.01% | 1072 |
|
|
2025
Q1 | $9.98M | Sell |
253,094
-64,469
| -20% | -$2.17M | ﹤0.01% | 1407 |
|
|
2024
Q4 | $9.56M | Sell |
317,563
-29,494
| -8% | -$846K | ﹤0.01% | 1608 |
|
|
2024
Q3 | $8.12M | Buy |
347,057
+207,723
| +149% | +$4.54M | ﹤0.01% | 1633 |
|
|
2024
Q2 | $2.48M | Sell |
139,334
-17,046
| -11% | -$272K | ﹤0.01% | 1992 |
|
|
2024
Q1 | $2.38M | Sell |
156,380
-271,633
| -63% | -$4.33M | ﹤0.01% | 2428 |
|
|
2023
Q4 | $7.31M | Sell |
428,013
-9,629
| -2% | -$112K | ﹤0.01% | 1773 |
|
|
2023
Q3 | $3.66M | Sell |
437,642
-45,440
| -9% | -$633K | ﹤0.01% | 1524 |
|
|
2023
Q2 | $12M | Sell |
483,082
-307,011
| -39% | -$7.93M | 0.01% | 915 |
|
|
2023
Q1 | $11.9M | Buy |
790,093
+274,125
| +53% | +$4.16M | 0.01% | 1085 |
|
|
2022
Q4 | $6.1M | Sell |
515,968
-76,161
| -13% | -$553K | ﹤0.01% | 1484 |
|
|
2022
Q3 | $3.5M | Buy |
592,129
+262,360
| +80% | +$1.72M | ﹤0.01% | 1382 |
|
|
2022
Q2 | $1.4M | Buy |
329,769
+189,478
| +135% | +$1.18M | ﹤0.01% | 2097 |
|
|
2022
Q1 | $1.33M | Sell |
140,291
-78,104
| -36% | -$904K | ﹤0.01% | 2181 |
|
|
2021
Q4 | $4.15M | Buy |
218,395
+118,164
| +118% | +$3.07M | ﹤0.01% | 1844 |
|
|
2021
Q3 | $3.34M | Buy |
100,231
+75,588
| +307% | +$2.34M | ﹤0.01% | 1921 |
|
|
2021
Q2 | $956K | Sell |
24,643
-96,666
| -80% | -$3.8M | ﹤0.01% | 2689 |
|
|
2021
Q1 | $5.85M | Buy |
121,309
+60,120
| +98% | +$2.89M | ﹤0.01% | 1395 |
|
|
2020
Q4 | $3.18M | Sell |
61,189
-420,827
| -87% | -$14.2M | ﹤0.01% | 1862 |
|
|
2020
Q3 | $12.9M | Sell |
482,016
-441,933
| -48% | -$10.2M | 0.01% | 918 |
|
|
2020
Q2 | $18M | Buy |
923,949
+63,030
| +7% | +$1.02M | 0.01% | 689 |
|
|
2020
Q1 | $8.47M | Buy |
860,919
+67,497
| +9% | +$853K | 0.01% | 1094 |
|
|
2019
Q4 | $8.81M | Buy |
793,422
+631,210
| +389% | +$4.8M | ﹤0.01% | 1498 |
|
|
2019
Q3 | $910K | Buy |
162,212
+96,449
| +147% | +$672K | ﹤0.01% | 3755 |
|
|
2019
Q2 | $569K | Buy |
65,763
+47,722
| +265% | +$361K | ﹤0.01% | 4207 |
|
|
2019
Q1 | $145K | Sell |
18,041
-33,217
| -65% | -$180K | ﹤0.01% | 5070 |
|
|
2018
Q4 | $210K | Buy |
51,258
+26,377
| +106% | +$131K | ﹤0.01% | 4541 |
|
|
2018
Q3 | $140K | Buy |
24,881
+15,298
| +160% | +$175K | ﹤0.01% | 5285 |
|
|
2018
Q2 | $126K | Sell |
9,583
-13,721
| -59% | -$189K | ﹤0.01% | 5083 |
|
|
2018
Q1 | $331K | Buy |
23,304
+12,053
| +107% | +$154K | ﹤0.01% | 4372 |
|
|
2017
Q4 | $93K | Sell |
11,251
-14,670
| -57% | -$128K | ﹤0.01% | 5297 |
|
|
2017
Q3 | $307K | Sell |
25,921
-28,156
| -52% | -$321K | ﹤0.01% | 4054 |
|
|
2017
Q2 | $543K | Buy |
54,077
+53,265
| +6,560% | +$596K | ﹤0.01% | 3446 |
|
|
2017
Q1 | $9K | Sell |
812
-1,301
| -62% | -$9.34K | ﹤0.01% | 6118 |
|
|
2016
Q4 | $10K | Buy |
2,113
+1,183
| +127% | +$6.94K | ﹤0.01% | 5904 |
|
|
2016
Q3 | $8K | Buy |
930
+889
| +2,168% | +$5.72K | ﹤0.01% | 5873 |
|
|
2016
Q2 | $0 | Sell |
41
-12,034
| -100% | -$97.8K | ﹤0.01% | 6626 |
|
|
2016
Q1 | $97K | Buy |
12,075
+11,894
| +6,571% | +$104K | ﹤0.01% | 4375 |
|
|
2015
Q4 | $2K | Sell |
181
-1,633
| -90% | -$20.6K | ﹤0.01% | 5765 |
|
|
2015
Q3 | $18K | Sell |
1,814
-4,606
| -72% | -$68.6K | ﹤0.01% | 5512 |
|
|
2015
Q2 | $103K | Buy |
6,420
+554
| +9% | +$8.77K | ﹤0.01% | 4652 |
|
|
2015
Q1 | $87K | Sell |
5,866
-177,685
| -97% | -$2.69M | ﹤0.01% | 4944 |
|
|
2014
Q4 | $2.75M | Buy |
183,551
+182,079
| +12,369% | +$2.37M | ﹤0.01% | 2241 |
|
|
2014
Q3 | $14K | Buy |
1,472
+1,067
| +263% | +$9.89K | ﹤0.01% | 6703 |
|
|
2014
Q2 | $4K | Sell |
405
-277
| -41% | -$1.77K | ﹤0.01% | 7206 |
|
|
2014
Q1 | $4K | Buy |
682
+337
| +98% | +$2K | ﹤0.01% | 7286 |
|
|
2013
Q4 | $1K | Sell |
345
-236
| -41% | -$953 | ﹤0.01% | 7451 |
|
|
2013
Q3 | $3K | Sell |
581
-89
| -13% | -$544 | ﹤0.01% | 7122 |
|
|
2013
Q2 | $4K | Buy |
+670
| New | +$4.29K | ﹤0.01% | 7413 |
|
Other funds holding TGTX
VPM
VCM
SCM
CAM
Barclays's TGTX Position: Q1 2026 in Review
Barclays reduced its TG Therapeutics (TGTX) stake by 74% in Q1 2026, selling an estimated $9.84M and leaving 116,657 shares worth $3.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1976.
Barclays first reported a position in TGTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $22.3M in Q2 2025. 364 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.
- Barclays held 116,657 shares of TG Therapeutics worth $3.88M as of Q1 2026.
- Barclays sold 330,063 TG Therapeutics shares in Q1 2026, an estimated $9.84M.
- TG Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1976 holding.
- Barclays first reported a position in TG Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Barclays's TG Therapeutics position peaked at $22.3M in Q2 2025.
- 364 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.